|
Cancer, which originates because of a deficiency in the above mentioned structures, will be much more effectively treated, through a mechanism that will compensate for the deficiency which led to DNA repair failure, than by utilizing a cytotoxic approach
Epidemiological Studies. There are hundreds of well documented epidemiological studies, showing an inverse correlation between cancer incidence and the consumption of fruit and vegetables. Based on these results, we have undertaken the screening of a significant amount of molecular structures, isolated from a large variety of fruit and vegetables in common use. We have used many of the standard analytical chemistry methods available today, to determine DNA-food molecular interactions. This research has guided us to identify substances, present in fruit and vegetables, which are essential for the activation of the enzymatic DNA repair mechanisms in a cancer cell.
Experimental observations We added our extract formulations to the culture media of various cancer cell lines. The results led us to understand about the different anti-tumour activities present in each one of these formulations.
Food Biochemistry Research. The contribution of Food Biochemistry Research in the development of new strategies to treat cancer can be divided in accordance with the activity of 3 different types of chemical compounds.
1.– Plant Kingdom Anti-tumour Molecules. These are chemicals found in the plant kingdom from where a medicinal substance, with anti-tumour properties, can be isolated, extracted and used as a medicinal tool to treat cancer.
2.– Mutagens in Nature and Carcinogenic Molecules in Cooked Foods. These are chemicals present in processed food and sometimes in nature that, after being isolated, characterized and analyzed, through molecular biology methods, are found to have a carcinogenic or mutagenic effect.
3.– Anti-Tumour Molecules of Natural Origin These are chemicals present, mainly in fruit and vegetables, in common consumption and of use in producing either a cancer chemopreventive or a cancer chemotherapeutic effect. These substances differ from the plant kingdom chemicals (category 1), in that they do not originate from rare species of plants, usually with a potent cytotoxic effect. They are, instead, present in foodstuffs of daily and common use, at micromolar concentrations, detectable only through newly developed methods of analytical, biophysical and nuclear chemistry spectroscopy.
The clinical trial we are proposing, for your consideration, is based on the use of natural substances. Most drugs in use today, reach clinicians at the final stage of development. More than 60% of all drugs in use today, to treat cancer, are based on natural compounds. However, because the substances in nature, from which they originate, are hardly ever mentioned by the manufacturers, there is a misconception about as to the contribution any natural product can provide in the struggle against cancer.
Induction of Cell Differentiation. While a cytotoxic compound will show an immediate decrease in tumour size, due to the direct interference with cell replication, a food chemotherapeutic compound stops proliferation by first inducing the differentiation of cancer cells. An MRI, CAT or Ultrasound scan assessment of this treatment will show a response similar in principle to that reported by Cloughesy and Woods, with the use of a biological agent for malignant glioma. Here, there was a slow and delayed anti-tumour effect, reaching its peak response, 9 months after the treatment was initiated. However, we have observed that, with the treatment we propose, tumours do not show any further growth in size as early as 15 days after the treatment has properly started. Cancer cells are induced to differentiate, therefore, the proliferative process ceases almost immediately. The reduction in the size of the tumour is however, a much slower process. Cancer cells are not rapidly killed, but induced to initiate the normal maturation paths, leading to their programmed death.
We report, in the following enclosure of this presentation, the clinical history and results on 11 advanced cancer patients, in whom, a GC10-100 intervention produced a cessation in tumour growth, in various aggressive forms of cancer.
|